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Objective: The present study sought to investigate the effect of micronized resveratrol 30 
supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 31 
(PON1) activity in patients with type 2 diabetes (T2D). 32 
Methods: In this double-blinded randomized trial, 76 patients with T2D were recruited. 33 
Participants were randomly assigned to consume 1000 mg resveratrol or placebo capsules 34 
(methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were 35 
measured at the beginning and end of the intervention using the ELISA method. In total, 71 36 
participants completed the study. 37 
Results: Our results showed that resveratrol significantly decreased serum levels of ADMA (-38 
0.16±0.11, P<0.001) and improved PON1 enzyme activity (15.39±13.99, P<0.001) compared with 39 
placebo, after adjusting for confounding factors (age, sex and baseline body mass index). 40 
Conclusion: Our findings suggest that 8-week resveratrol supplementation may produce 41 
beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. 42 
However, further research is needed to confirm the veracity of these results. 43 







Type 2 diabetes (T2D), the most prevalent endocrine disease, represents one of the most important 49 
health issues affecting people globally (1, 2). Empirical evidence indicates that cardiovascular 50 
disease is a major cause of mortality and morbidity in patients with diabetes (3). Obesity, 51 
dysglycemia, dyslipidemia, and hypertension represent the most important risk factors for 52 
cardiovascular diseases, which are especially common in diabetic patients (4). The vascular 53 
endothelium plays a pivotal role in maintaining the vascular tone and mediates production (5). One 54 
of the mediators is nitric oxide (NO), which is produced in response to stress, and has an important 55 
function in vasodilatation and increases circulation (6). Asymmetric dimethylarginine (ADMA) is 56 
a competitive endogenous inhibitor for nitric oxide synthase (NOS) and inhibits the production of 57 
NO in pathological concentrations (7). Increased serum levels of ADMA have been reported in 58 
patients with diabetes, renal failure, hypercholesterolemia, cardiovascular diseases, and 59 
hypertension (8).  60 
Chronic hyperglycemia in T2D induces oxidative stress in various pathways, such as; glucose 61 
auto-oxidation, glycosylation of operational proteins, activation of the polyol pathway, endothelial 62 
NOS (eNOS) uncoupling and oxidative phosphorylation (9-12). Paraoxonases (aryl dialkyl 63 
phosphatase) as antioxidant factors, also initially identified as hydrolyzing enzymes of 64 
organophosphorus compounds such as, paraoxon, or diazoxone insecticides (13, 14). Paraoxonase-65 
1 (PON1) is an esterase which is produced in the liver and is transported with circulating high-66 
density lipoprotein (HDL) (15, 16). It seems that PON1 is partly responsible for the antioxidant 67 
property of HDL (17). Some studies have shown that the PON1 activity is independent of the 68 
amount of Apo-lipoprotein HDL (18); PON1 also inhibits LDL peroxidation and oxidized LDL 69 
synthesis (19), and hydrolyzes homo-cysteine, which is an important risk factor for cardiovascular 70 
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disease (20). PON1 activity is important in the prevention of atherosclerosis progression by 71 
inhibition of MCP-1 production (Monocyte Chemoattractant Peptide 1), which is stimulated by 72 
oxidized LDL in the endothelial cells (21). Some previous studies have reported that PON1 73 
enzyme activity may be decreased in diabetic patients (22-24), whilst high serum levels of glucose 74 
can lead to PON1 separation from HDL (25). Furthermore, it seems that serum levels of ADMA 75 
and PON1 activity are affected by antioxidants (26).  76 
Resveratrol is a polyphenol found mostly in grapes and nuts and has been shown to elicit beneficial 77 
effects on diabetes and cardiovascular diseases (27, 28). The cardiovascular protective effects of 78 
resveratrol have been widely investigated; however, the exact mechanisms are far from 79 
consensual. The results of some meta-analytical studies have shown that resveratrol 80 
supplementation can elicit improvements in endothelial function (29), and reductions in 81 
inflammatory markers (30-32); however, a previous meta-analysis concluded that resveratrol 82 
supplementation has no significant effects on cardiovascular risk factors (33). In the present study, 83 
we investigated the effects of resveratrol supplementation on serum levels of ADMA and PON1 84 
activity in patients with type 2 diabetes. 85 
 86 
MATERIALS AND METHODS 87 
Study Design and Participants 88 
Patients with T2D were selected from a diabetes center (Yazd, Iran), and the diagnosis of 89 
diabetes was confirmed by an endocrinologist (34). The protocol of the present double-blind 90 
randomized controlled trial was approved by the Ethics Committee of Shahid Sadoughi 91 
University of Medical Sciences in Yazd (IR.SSU.SPH.REC.1397.073) and registered in the 92 
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Iranian Registry of Clinical Trials (www.irct.ir) asIRCT20171118037528N1). Informed consent 93 
was provided by all participants prior to study commencement.  94 
Inclusion and Exclusion Criteria 95 
Detailed information about the study design has been previously described in detail (35). Briefly, 96 
men and women with T2D aged 30-60 years old, body mass index (BMI) of 25-30 kg/m2, and 97 
glycated hemoglobin (HbA1c) lower than 8% were enrolled in the study. Exclusion criteria 98 
included; diagnosed kidney or liver disease, cancer, Alzheimer's, gastrointestinal ulcer, 99 
inflammatory and autoimmune diseases, and/or history of myocardial infarction, treatment with 100 
any supplement containing antioxidants, insulin, fibrates, warfarin, aspirin or any drugs that inhibit 101 
platelet aggregation in the 6 months preceding the study. Patients who consumed alcoholic 102 
beverages habitually, and pregnant or lactating women were also excluded. 103 
Setting  104 
A stratified randomized method, using a computer random generated number based on sex and age 105 
(30-45, 45-60 years old), was used to assign participants into the intervention or control group, 106 
respectively. Patients in the intervention group received two capsules per day, which provided 107 
1000 mg/day purified resveratrol (Mega-Resveratrol, Danbury, USA) for 8 weeks. Two capsules 108 
containing methyl cellulose (Barij essence, Kashan, Iran) were taken by patients in the control 109 
group for the same duration. The placebo was similar in appearance and taste with the resveratrol 110 
supplement. Patients were not deprived of their usual treatment for diabetes. 111 
A person outside the research team performed the packing and labeling (A or B) of the bottles 112 
containing resveratrol and placebo. The researchers and participants were not aware of the contents 113 
until the end of the intervention. Patients were asked to report any suspected adverse events. The 114 
compliance rate of the participants was evaluated using the remaining capsule counts at the end of 115 
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the study, and participants were asked to maintain their habitual diet and physical activity 116 
throughout the study.  117 
Nutritional and Physical Activity Assessment 118 
To assess nutrient intake, two, 3-day dietary food records (one weekend day and two weekdays) 119 
were completed by the participants in the first and last week of the intervention. Data were 120 
analyzed using Nutritionist IV software (The Hearst Corporation, San Bruno, California, USA). 121 
To assess the physical activity level, metabolic equivalent (MET) was calculated using a validated 122 
questionnaire at the beginning and end of the study (36). In this questionnaire, information on 123 
physical activity is classified based on the intensity of each activity in nine different categories 124 
(ranging from inactivity to severe sports activities). The duration of each activity was multiplied 125 
by the coefficient for each activity, and the values obtained in the nine different classes were 126 
summed in order to provide MET/h per day.  127 
Anthropometric and Biochemical Measurements 128 
Anthropometric measures, including height, body weight, waist and hip circumferences, BMI, fat 129 
and, fat-free masses, were assessed before and after the intervention using a segmental body 130 
composition analyzer (Tanita BC‐418, Tokyo, Japan). The results of the anthropometric measures, 131 
as well as cardio-metabolic biochemical factors (glycemic indices and lipid profile), have been 132 
reported elsewhere (37).  133 
Blood samples for biochemical parameters were collected at the beginning and end of the study 134 
after 12h nocturnal fasting. Blood samples were centrifuged for 10 minutes at room temperature 135 
(3000 g; Eppendorf AG, Hamburg), and then the serum samples were frozen at -70 ° C until 136 
analyses. Serum levels of ADMA were measured applying enzyme-linked immunosorbent assay 137 
(ELISA) method using a commercially available kit (Zellbio, Germany) with inter-and intra-138 
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assay<12% and <10%, respectively. The PON1 activity also determined by the ELISA method 139 
using a commercially available kit (Zellbio, Germany, inter-and intra-assay: CVs were 4.8% and 140 
4.1%, respectively).  141 
Sample Size and Statistical Analysis  142 
This report is part of a previous study that calculated the sample size based on the PPARα gene 143 
expression in peripheral blood mononuclear cells (35). Although, a retrospective power analysis 144 
was performed to assess the quantity of the sample size for our interested outcomes. The results 145 
showed adequate power for ADMA levels (observed power= 1.0). 146 
SPSS software for windows version 23.0 (SPSS, Chicago, IL, USA) was used for all data entry 147 
and statistical analyses. The values were expressed as mean ± standard deviation for continuous 148 
and proportions for categorical data. The Kolmogorov-Smirnov test was used to evaluate the 149 
distribution of variables. To compare the quantitative values between the two groups, an 150 
independent samples t-test and within groups paired t-test were used, respectively. Analysis of 151 
covariance (ANCOVA) was used to modify possible confounding factors including age, gender, 152 
and baseline BMI. Statistical significance was accepted, a priori, at P <0.05. 153 
RESULTS 154 
Of the 76 participants enrolled in the study, five patients did not complete the intervention due to 155 
pregnancy (n=1), traveling (n=1) and withdrawal of consent (n=3). Finally, data from 71 156 
participants (35 patients in resveratrol and 36 patients in placebo groups) were included in the 157 
analysis (Figure 1). More than 90% compliance (92.6% in placebo and 93.1% in resveratrol) was 158 
detected through capsule counting, and no adverse side effects were reported. 159 
Table 1 details the general characteristics of the participants before the intervention, and there 160 
were no significant differences in baseline variables between the two groups. The mean age of 161 
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participants in resveratrol and placebo groups was 50.14 ± 7.38 and 50.06 ± 7.69 years, 162 
respectively. No significant between-group differences for dietary intake and physical activity 163 
were observed at the baseline and they also did not change following the 8-week intervention 164 
(Table 2). 165 
Resveratrol significantly reduced ADMA levels compared with baseline and the placebo group (-166 
0.16±0.11 (ng/ml); all P-values<0.001). PON1 activity was also significantly increased after 167 
supplementation in the resveratrol group (15.39±13.99 (U/L); P<0.001) and compared with the 168 
placebo group (P=0.04). These findings remained significant after adjusting for confounding 169 
variables (all P-values<0.001) (Table 3). 170 
DISCUSSION 171 
 The results of the current study showed a significant reduction in serum levels of ADMA, and 172 
significant increase in PON1 activity, following 8-week resveratrol supplementation. In line with 173 
our findings, previous studies have reported a significant increase in PON1 activity after 174 
resveratrol (38), pomegranate juice (39), eicosapentaenoic acid (40), barberry juice (41), and 175 
vitamin E supplementation (42) in patients with type 2 diabetes. Furthermore, one study reported 176 
a higher intake of fruit and vegetable leads to an increase in PON1 activity (43). The findings of 177 
some in-vitro studies have also showed that resveratrol increases PON1 gene expression and 178 
activity in different human cells (44-46). 179 
PON1 is a HDL-associated enzyme that hydrolyzes oxidized LDL-cholesterol, and is known for 180 
its atheroprotective capabilities (47). Furthermore, this enzyme plays a critical role in the 181 
protection against oxidative stress-related diseases (48, 49); including cardiovascular diseases, the 182 
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major cause of mortality among patients with diabetes (50). Moreover, the activity and 183 
concentration of PON1 are reported to decrease in these patients (23).  184 
Resveratrol is an antioxidant that appears to affect PON1 activity through several pathways. 185 
Resveratrol can result in an increase in carnitine palmitoyl transferase-1, decrease in acetyl-CoA 186 
carboxylase and fatty acid synthase genes expression, and, consequently, an elevation in HDL 187 
levels (38). The results of the present study also support the beneficial effect of resveratrol on HDL 188 
levels (37). Furthermore, it seems that resveratrol might regulate gene expression by binding to 189 
the estrogen response element-2 sequences (51). There are similar sequences in the promoter 190 
region of PON1 gene, suggesting that PON1 gene expression upregulation induced by resveratrol 191 
may be related to the presented sequences (52). Moreover, resveratrol is known as a ligand for 192 
aryl-hydro carbon receptors (AhR) and can increase PON1 gene expression and activity through 193 
AhR-dependent mechanisms (53).  194 
In the present study, we also observed a significant reduction in serum levels of ADMA following 195 
resveratrol supplementation. Previous reports have identified that increased ADMA levels are 196 
associated with oxidative stress related diseases, such as diabetes (54-56). ADMA is produced via 197 
protein arginine methyl transferase and breaks down to citrulline and dimethyl amine by dimethyl 198 
arginine dimethyl amino hydrolase (DDAH). Oxidative stress reduces the gene expression and 199 
activity of DDAH resulting in endothelial dysfunction (57, 58), whilst there is substantive evidence 200 
that increased ADMA levels contribute to injuries induced by oxidative stress (59). There are 201 
numerous reports in the literature asserting that resveratrol can stimulate eNO synthesis and inhibit 202 
its degradation in several mechanisms (60-62). However, one study suggested that the levels of 203 
eNOS did not significantly change following resveratrol supplementation (63); conceivably due to 204 
the small sample size (n=48). Resveratrol activates sirtuin-1 (SIRT1) through AMP-activated 205 
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protein kinase (AMPK) pathway (64), and SIRT-1 increases eNOS gene expression by 206 
deacetylating Forkhead box O (FOXO) transcription factors (65). It has been shown that elevated 207 
NO levels can upregulate DDAH by cyclic GMP induction and subsequently decreased ADMA 208 
levels (66). There is also some evidence that resveratrol can independently upregulate DDAH gene 209 
expression (67); however, the molecular mechanisms are not well identified. Moreover, DDAH 210 
upregulation causes decreases ADMA levels and increases NO production and bioavailability (58, 211 
68).  212 
A number of in-vitro studies in endothelial cells have reported significant decreases in ADMA 213 
levels after red wine consumption as a source of resveratrol (58). Some RCTs have also shown 214 
that ADMA levels are reduced after coenzyme Q10 (69), alpha-lipoic acid (70, 71), 215 
eicosapentaenoic acid (72), and DHA-enriched fish oil consumption (73) in patients with type 2 216 
diabetes, respectively, and also vitamin E supplementation in chronic kidney disease patients (74). 217 
Moreover, one animal study indicated DDAH activity increased after intervention with trans-3, 5, 218 
4'-trihydroxystilbene as an analog of resveratrol on gastric mucosal injury (67). However, the 219 
results of some studies are inconsistent with our results. For instance, one study indicated that 220 
vitamin C and E did not affect ADMA levels in children with hyperlipidemia (75), whilst another 221 
study reported no significant differences in PON1 activity when omega-3 was administered (76). 222 
However, the small number of participants may justify the aforementioned findings.  223 
To the authors’ knowledge, this is the first clinical trial study to investigate the effect of resveratrol 224 
supplementation on serum levels of ADMA. Although there is one RCT investigating the effect of 225 
resveratrol on PON1 activity in patients with diabetes (38), we utilized micronized resveratrol to 226 
increase bioavailability, and included patients with overweight exclusively, to adjust oxidative 227 
stress induced by obesity. Stratification by gender and age also permitted us to control confounders 228 
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related to these factors. Despite the novelty of the present study, there are some limitations that 229 
must be considered. The present study was designed for short-term assessment of resveratrol 230 
supplementation effects; thus, we have no information as to the longer-term effects, or dose-231 
response relationship beyond this time. Finally, we did not investigate the cellular pathways related 232 
to the beneficial effects of resveratrol on our interested outcomes; which clearly represents an 233 
avenue for future research. 234 
Conclusion 235 
The findings of the present study demonstrated that 8-week resveratrol supplementation can 236 
significantly improve ADMA levels and enhance PON1 activity in patients with diabetes. These 237 
findings may support the beneficial, atheroprotective, effects of resveratrol; although, more  238 
research is needed to confirm the veracity of our findings.  239 
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Figure 1. CONSORT diagram outlining the number of subjects involved in enrollment, 501 
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Allocated to placebo group (n= 38) 
 







Randomized (n= 76) 
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(n= 36) P-value2 
Age (years) 50.14 ± 7.38 50.06± 7.69 0.96 
Diabetes duration (years) 9.40 ± 7.07 8.11 ± 6.90 0.44  
Gender (female), n (%) 15 (42.9) 16 (44.4) 0.89  
Menopause status, n (%) 4 (26.6) 3 (18.8) 0.68 








Complications    
Hypertension, n (%) 11 (31.4) 7 (19.4) 0.24 
Kidney stone, n (%) 2 (5.7) 3 (8.3) 0.66  
Non-alcoholic fatty liver, n (%) 3 (8.6) 2 (5.6) 0.62  
Neuropathy, n (%) 2 (5.7) 2 (5.6) 0.97 
Retinopathy, n (%) 5 (14.3) 5 (13.9) 0.96 
Family T2DM History, n (%) 25 (71.4) 30 (83.3) 0.23  
Medications    
Metformin, n (%) 30 (85.7) 31 (86.1) 0.96  
Glibenclamide, n (%) 11 (31.4) 16 (44.4) 0.25  
Statins, n (%) 3 (8.6) 4 (11.1) 0.70  
Blood pressure lowering drugs, n (%) 6 (17.1) 5 (13.9) 0.72 
Anthropometric measures    
Weight (kg) 73.69± 8.24 72.71± 10.52 0.66 
Height (cm) 164.94 ± 7.22 162.08 ± 11.29 0.20 
BMI (kg m-2) 27.10± 2.69 27.66± 2.71 0.39 
HC (cm) 101.97± 6.05 103.47± 8.04 0.37 
WC (cm) 91.75± 7.4 92.58± 8.53 0.66 
WHR 0.9± 0.06 0.89± 0.05 0.53 
WHtR 0.55± 0.05 0.57± 0.07 0.25 
1Data are expressed as mean ± SD for continuous variables or as frequency and percentage for categorical variables. 508 
2Differences between the control and intervention groups were evaluated using the Independent sample t-test for continuous 509 
variables and chi-square test for categorical variables.BMI, Body mass index; HbA1c, glycated hemoglobin; HC, Hip 510 




Table 2. Dietary intake and physical activity during study in resveratrol and placebo groups (mean ± SD) 513 
1The presented P-values are associated with within-group comparisons obtained paired t test.  514 
2The presented P-values are associated with baseline comparisons of the resveratrol and control groups obtained independent 515 
sample t test 516 
EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; MUFA, Mono-unsaturated fatty acid; PA, physical activity. 517 
PUFA, Poly-unsaturated fatty acid. 518 
Variable 









Energy (kcal) 1612.87± 587.87 1544.71± 597.37 0.45 1708.79± 515.39 1674.16±597.07 0.55 0.47 
Carbohydrate (%) 59.76 ± 12.71 61.36± 11.2 0.43 60.82 ± 9.96 60.61± 8.76 0.88 0.7 
Protein (%) 15.5 ± 4.65 16.28± 5.17 0.47 15.48 ± 3.48 15.84± 4.02 0.56 0.97 
Fat (%) 25.34 ± 14.55 24.14± 11.02 0.58 24.61 ± 10.42 24.26± 9.63 0.77 0.81 
Fiber (g/d) 9.43± 4.11 9.69± 4.32 0.81 10.44± 5.23 10.86±5.27 0.64 0.2 
Cholesterol (mg/d) 219± 29 208± 47 0.77 189± 71 191± 63 0.61 0.75 




Vitamin E  
































































Table3: Comparison of serum levels of ADMA and PON1 enzyme activity at baseline and after intervention in resveratrol and placebo groups (mean ± SD). 
 
1The presented P-values are associated with within-group comparisons obtained paired t test.  
2The presented P-values are associated with baseline comparisons of the resveratrol and control groups obtained independent sample t test 
3The presented P-values are associated with between groups comparisons after intervention obtained independent sample t test. 
4 The presented P-values are associated with mean changes comparisons obtained from independent-sample t test. 
5 The presented P-values are associated with mean changes comparisons adjusted for age, gender, and BMI obtained from analysis of covariance (ANCOVA).  
ADMA, asymmetric de-methyl-arginine; PON1,  paraoxonase 1. 
Variable 
















ADMA (ng/ml) 0.61±0.47 0.44±0.38 0.000 -0.16±0.11 0.60±0.45 0.57±0.26 0.06 
 
0.04±0.07 0.527 0.000 0.000 0.000  
PON1 (U/L) 97.32±18.68 112.72±24.91 0.000 15.39±13.99 100.12±24.60 101.06±24.14              0.223 
 
0.94±4.95  
 
0.592 
 
0.049 
 
0.000 
 
0.000 
